Stryker’s European Problem: How Hard Can This Be?

Stryker corporation is a big device player with orthopaedics, spine and neuro business to name three. Yet it’s European effort continues to result in falling share and disappointment. Recent management changes haven’t yet borne fruit, but the company is expecting better times ahead. While the medtech business can be a complicated affair, we suggest basic business principles still surely apply.

TranS1’s Gloomy Q2 Financials

TranS1’s technology is intriguing enough to keep on capturing our attention, but its revenue and gross margin picture for Q2 2012 are not painting a picture of growth. Encouraging words from the boss though.

HeartWare’s Increased Losses Signal Investment As Revenue Ramps

HeartWare International Inc. has announced revenue of $29.1 million for the second quarter ended June 30, 2012, representing a 42 percent increase from $20.4 million in revenue for the same period of 2011. However the company recorded a net loss more than double prior year as it invested in R&D and commercialisation activity.

Looks Like Restructuring Is Paying Off As Smith & Nephew Delivers Strong Financials

Financial key performance indicators for S&N’s quarter, when set against the equivalent period a year ago show revenue of $1,029 million, up 2% on an underlying basis, trading profit of $234 million, up 6% on an underlying basis, with trading profit margin up 80 bps to 22.7% as Advanced Surgical Devices (ASD) division restructuring benefits come through

MiMedx Group Turns A profit From Human Amniotic Membrane

Georgia’s Mimedx Group is a developer of biomaterial solutions for surgical repair of soft tissues using human amniotic membrane. Pretty specialised field and never likely to be sponsoring the Olympics, but nonetheless the company’s recently stated Q2 financials suggest it’s in good shape, having grown consistently and turned red numbers black in the past twelve months.

Edwards’Q2 Sales Growth Driven Entirely By Sapien

Edwards Lifesciences Corporation has released its second quarter financial results which are, on face value, bucking the trend by showing sales growth of almost 16% (albeit excluding currency impact) to $482m compared with the equivalent period last year. Closer examination reveals that growth is almost exclusively related to the company’s Sapien transcatheter heart valve, launched in U.S and seeing continued growth internationally.